Exposure to tissue culture conditions can adversely affect myoblast behavior in vivo in whole muscle grafts: Implications for myoblast transfer therapy

Cell Transplantation

Volumn 9, Issue 3, 2000, Pages 379-393

  Smythe, G M ^a   Grounds, M D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Myoblast; Myoblast transfer therapy; Myotube; Tissue culture; Whole muscle graft

Indexed keywords

DESMIN; DNA; PROTEINASE; REAGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DNA SEQUENCE; EXPOSURE; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUSCLE GRAFT; MUSCLE REGENERATION; MUSCLE TRANSPLANTATION; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE;

ANIMALIA;

EID: 0033842201     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.1177/096368970000900309     Document Type: Article

References (75)

1. A serum free medium that supports the growth of cultured skeletal muscle satellite cells
2. Effects of leukaemia inhibitory factor and other cytokines on murine and human myoblast prolieration
3. Calpain and calpastatin in myoblast differentiation and fusion: Effects of inhibitors
4. The calpain-calpastatin system and protein degradation in fusing myoblasts
5. The role of calpastatin (the specific calpain inhibitor) in myoblast differentiation and fusion
6. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source
7. A dualmarker system for quantitative studies of myoblast transplantation in the mouse
8. Chemotaxis of skeletal muscle satellite cells
9. The role of growth factors in myoblast transfer therapy
10. Potential m-calpain substrates during myoblast fusion
11. Myoblast fusion requires fibronectin degradation by exteriorized m-calpain
12. Evidence for fibronectin degradation by calpain II
13. A potential alternative strategy for myoblast transfer therapy: The use of sliced muscle grafts
14. Rapid death of injected myoblasts in myoblast transfer therapy
15. A serum free medium for the growth of muscle cells in culture
16. Disruption of epithelial cell-matrix interactions induces apoptosis
17. Integrins and anoikis
18. Control of adhesion-dependent cell survival by focal adhesion kinase
19. Serum-free culture conditions for analysis of secretory proteinases during myogenic differentiation of mouse C2C12 myoblasts
20. Transplantation in the mouse modelthe use of a Y-chromosome-specific DNA clone to identify donor cells in situ
21. Commentary on the present state of knowledge for myoblast transfer therapy
22. Phagocytosis of necrotic muscle in muscle isografts is influenced by the strain, age and sex of host mice
23. A comparison of muscle precursor replication in crush-injured skeletal muscle of Swiss and Balbc mice
24. The expression of extracellular matrix during adult skeletal muscle regeneration: How the basement membrane, interstitium, and myogenic cells collaborate
25. Control of inflammatory damage by anti-LFA-1: Increased success of myoblast transplantation
26. Prevention by anti-LFA-1 of acute myoblast death following transplantation
27. Synthesis and secretion of matrix-degrading metalloproteases by human skeletal muscle satellite cells
28. The fate of individual myoblasts after transplantation into muscles of DMD patients
29. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation
30. Serum free media for growth and differentiation of human muscle satellite cells
31. Improved media for normal human satellite cells: Serum free clonal growth and enhanced growth with low serum
32. Long term maintenance of primary myogenic cultures on a reconstituted basement membrane
33. Why do lonely myoblasts die? DNA quantitation shows enhanced survival of donor male myoblasts in host mice depleted of CD4+/CD8+ or NK1.1 cells
34. Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions
35. Human myoblast transplantation in immunodeficient and immunosuppressed mice: Evidence of rejection
36. Myoblast transplantation in the mouse: What cells do we use?
37. Myoblast transfer in Duchenne muscular dystrophy
38. Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve
39. Myoblast transplantation in monkeys: Control of immune response by FK506
40. Functional dissociation of anoikis-like cell death and activity of stress activated protein kinase
41. Expression of perlecan, a proteoglycan that binds myogenic inhibitory basic fibroblast growth factor, is down regulated during skeletal muscle differentiation
42. Syndecan-1 expression is down-regulated during myoblast terminal differentiation
43. Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy
44. Feasibility, safety and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys
45. The identification of myogenic cells in skeletal muscle, with emphasis on the use of tritiated thymidine autoradiography and desmin antibodies
46. Experimental skeletal muscle grafts as a model of regeneration
47. Matrigel enhances myotube development in a serum-free defined medium
48. Extracellular matrix, growth factors, genetics: Their influence on cell proliferation and myotube formation in primary cultures of adult mouse skeletal muscle
49. Making informed choices: Medium, serum, and serum-free medium
50. Endotoxin is angiogenic
51. Extracellular matrix is required for skeletal muscle differentiation but not myogenin expression
52. Cellular differences in the regeneration of murine skeletal muscle: A quantitative histological study in SJL/J and BALB/c mice
53. α-Dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability
54. Endotoxins and disease mechanisms
55. Myoblast-based gene therapies
56. Invited review: Myoblast transfer: A possible therapy for inherited myopathies?
57. Modulation of activities and RNA level of the components of the plasminogen activation system during fusion of human myogenic satellite cells in vitro
58. Skeletal muscle transplants and models of muscle regeneration
59. The host environment determines strain-specific differences in the timing of skeletal muscle regeneration: Cross-transplantation studies between SJL/J and BALB/c mice
60. Initiation and duration of myogenic precursor cell replication in transplants of intact skeletal muscles: An autoradiographic study in mice
61. Enhanced donor myoblast migration and fusion in normal and dystrophic host muscle
62. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts
63. Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells
64. Microinjection of calpastatin inhibits fusion in myoblasts
65. Anoikis, extracellular matrix, and apoptosis factors in isolated cell transplantation
66. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy
67. Merosin and laminin in myogenesis: Specific requirement for merosin in myotube stability and survival
68. Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion
69. Insulin-like growth factor-I-mediated survival from anoikis: Role of cell aggregation and focal adhesion kinase
70. Myoblast fusion promotes the appearance of active protease nexin I on human muscle cell surfaces
71. Cyclosporin A as a means of preventing rejection of skeletal muscle allographs in mice
72. Functional effects of myoblast implantation into histoincompatible mice with or without immunosuppression
73. Myotube formation is delayed but not prevented in MyoD deficient skeletal muscle: Studies in regenerating whole muscle grafts of adult mice
74. The transition from proliferation to differentiation is delayed in satellite cells from mice lacking MyoD
75. A metalloprotease-disintegrin participating in myoblast fusion